Key Highlights
- IDEAYA Biosciences unveiled successful Phase 2/3 data for its darovasertib and crizotinib combination in metastatic uveal melanoma patients
- Median progression-free survival reached 6.9 months with the experimental combo compared to 3.1 months for current standard therapy
- The dual-drug regimen reduced disease progression risk by 58% versus standard care
- Response rates showed dramatic improvement: 37.1% for the combination versus only 5.8% for conventional treatment — including 5 complete responses with the combo and zero in the control group
- The company intends to submit its New Drug Application to the FDA during the latter half of 2026
Shares of IDEAYA Biosciences (IDYA) experienced a significant rally during Monday’s premarket session following the biotech company’s announcement of encouraging Phase 2/3 clinical trial outcomes for a dual-drug approach treating metastatic uveal melanoma — an uncommon and challenging-to-treat cancer originating in the eye.
IDEAYA Biosciences, Inc., IDYA
The clinical study evaluated darovasertib in combination with crizotinib. Data revealed the paired therapy delivered more than twice the median progression-free survival when compared against conventional treatment approaches.
Participants receiving the combination therapy achieved a median PFS of 6.9 months. In contrast, those on standard treatment managed only 3.1 months. This outcome successfully achieved the study’s primary objective.
Beyond doubling survival metrics, the combination reduced the likelihood of cancer advancement by 58%. Such figures typically capture significant attention from oncology-focused investors.
Impressive Results Across Secondary Measures
The secondary outcome measures proved equally compelling. Overall response rates registered at 37.1% among patients receiving the darovasertib combination, a stark contrast to the mere 5.8% seen with conventional therapy.
The combination arm recorded five complete responses among participants. Standard care produced none.
The median duration of response for the combination therapy measured 6.8 months. Researchers characterized the treatment as well-tolerated with a safety profile considered manageable.
Preliminary data also suggested a potential overall survival advantage for the combination versus standard treatment approaches, although complete data for this metric remains immature.
Metastatic uveal melanoma has long suffered from a dearth of effective therapeutic interventions. These findings establish darovasertib as a promising first-in-class treatment option for this condition.
Regulatory Submission Targeted for Second Half 2026
IDEAYA announced its intention to file a New Drug Application with the FDA during the second half of 2026, leveraging these trial outcomes.
This schedule positions a potential regulatory approval determination for sometime in 2027, contingent upon the FDA’s review timeline.
IDYA stock climbed as high as 26.36% during premarket activity, touching $38.60, based on Benzinga Pro data. Earlier market reports indicated gains around 15%, with shares trading approximately $35.
The equity had already been hovering near its 52-week peak of $41.02 prior to Monday’s disclosure. Throughout the past year, IDYA has appreciated roughly 78%.
Broader market sentiment leaned negative Monday morning, with S&P 500 futures declining approximately 0.6% concurrent with the premarket movement.
IDEAYA has scheduled a full trial data presentation at an upcoming medical conference, with additional details anticipated later in 2026.
